Table 1.
Summary of clinical efficacy.
| Cancer type | ARKS | ARKS | ARKS | ARKS | Recurrent Ovarian Cancer |
Metastatic Breast Cancer |
Multiple Myeloma |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | PLD1 | BV | PLD1 | ABV | PLD1 | PTX | PLD1 | HAART | PLD2 | TPN | PLD2 | DOX | DVd | VAd |
| No. of patients | 121 | 120 | 133 | 125 | 37 | 36 | 13 | 15 | 239 | 235 | 254 | 255 | 97 | 95 |
| CR (%) | 6.0 | 1.0 | 1.0 | 0.0 | 5.0 | 8.0 | 31.0 | 13.0 | 3.8 | 4.7 | - | - | 3.1 | 0.0 |
| PR (%) | 53.0 | 22.0 | 45.0 | 25.0 | 41.0 | 47.0 | 46.0 | 7.0 | 15.9 | 12.3 | - | - | 41.3 | 41.1 |
| OR (CR + PR, %) | 59.0 | 23.0 | 46.0 | 25.0 | 46.0 | 55.0 | - | - | 19.7 | 17.0 | 33.0 | 38.0 | 44.4 | 41.1 |
| Stable (%) | 38.0 | 68.0 | 53.0 | 67.0 | 32.0 | 25.0 | - | - | 32.2 | 40.4 | 25.0 | 25.0 | 39.2 | 48.4 |
| Progressive (%) | 0.0 | 4.0 | 2.0 | 8.0 | 3.0 | 3.0 | - | - | 48.1 | 42.6 | 18.0 | 11.0 | 2.1 | 0.0 |
| Not assessable (%) | 3.0 | 5.0 | 0.0 | 0.0 | 24.0 | 17.0 | - | - | - | - | 18.0 | 21.0 | 14.4 | 10.5 |
| PFS (months) | - | - | - | - | 12.2 | 17.5 | - | - | 3.8 | 4.0 | 6.9 | 7.8 | 78%* | 76%* |
| OS (months) | 5.3 | 5.3 | - | - | - | 53.6 | - | - | 14.0 | 13.2 | 21.0 | 22.0 | 88%* | 85%* |
| Ref. | [64] | [63] | [65] | [66] | [67] | [20] | [69] | |||||||
CR: Complete response; PR: Partial response; OR: Overall response; PFS: Progression free survival; OS: Overall survival; ARKS: AIDS-related Kaposi’s sarcoma; PLD1: Pegylated liposomal doxorubicin (20 mg/m2); PLD2: Pegylated liposomal doxorubicin (50 mg/m2); BV: bleomycin (15 IU/m2) and vincristine (2 mg); ABV: doxorubicin (20 mg/m2), bleomycin (10 mg/m2) and vincristine (1 mg); PTX: Paclitaxel (100 mg/m2); HAART: highly active antiretroviral therapy; TPN: Topotecan (1.5 mg/m2) ; DOX: Doxorubicin (60 mg/m2); DVd: pegylated liposomal doxorubicin (40 mg/m2), vincristine (1.4 mg/m2; maximum, 2.0 mg) and reduced-dose dexamethasone (40 mg); VAd: vincristine (0.4 mg) doxorubicin (9 mg/m2) and reduced-dose dexamethasone (40 mg); ‘-’ not available; ‘*’ 1 year PFS or OS rate [22], [65], [66], [67], [68], [69], [71]